CytomX Therapeutics (CTMX) Revenue (2014 - 2026)

CytomX Therapeutics (CTMX) has 13 years of Revenue data on file, last reported at $10.3 million in Q1 2026.

• Quarterly Revenue fell 79.85% year-over-year to $10.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.5 million (down 75.91% YoY) and the FY2025 annual result came in at $76.2 million, down 44.82% from the prior year.
• Revenue grew to $10.3 million in Q1 2026, from $663000.0 in the prior quarter.
• In the past five years, Revenue ranged from a high of $50.9 million in Q1 2025 to a low of $663000.0 in Q4 2025.
• A 5-year average of $22.3 million and a median of $23.5 million in 2023 frame the typical range for Revenue.
• Annual changes were most pronounced in 2023 — Revenue jumped 159.94% — and 2025, when it slumped 98.26%.
• Tracing CTMX's Revenue over 5 years: stood at $20.1 million in 2022, then jumped by 32.22% to $26.6 million in 2023, then surged by 43.17% to $38.1 million in 2024, then tumbled by 98.26% to $663000.0 in 2025, then surged by 1447.21% to $10.3 million in 2026.
• The last three Revenue figures came in at $10.3 million (Q1 2026), $663000.0 (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.